pyrroles has been researched along with Thromboembolism, Venous in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Charles-Schoeman, C; Hyde, C; Martin, DA; Paciga, SA; Sahin, B; Szekanecz, Z; Vranic, I; Wang, Z; Weitz, JI | 1 |
| Danese, S; Fan, H; Jones, TV; Koram, N; Lawendy, N; Modesto, I; Panés, J; Quirk, D; Reinisch, W; Sandborn, WJ; Sands, BE; Su, C | 1 |
| Morinobu, A | 1 |
| Desai, RJ; Kim, SC; Pawar, A; Weinblatt, ME | 1 |
| Cieśla-Dul, M; Potaczek, DP; Undas, A; Żółciński, M | 1 |
| Karska-Basta, I; Kubicka-Trząska, A; Romanowska-Dixon, B; Undas, A | 1 |
| Ciesla-Dul, M; Undas, A; Zolcinski, M | 1 |
1 review(s) available for pyrroles and Thromboembolism, Venous
| Article | Year |
|---|---|
JAK inhibitors for the treatment of rheumatoid arthritis.
Topics: Adamantane; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Benzofurans; Cardiovascular Diseases; Herpes Zoster; Humans; Janus Kinases; Molecular Targeted Therapy; Neutropenia; Niacinamide; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides; Venous Thromboembolism | 2020 |
1 trial(s) available for pyrroles and Thromboembolism, Venous
| Article | Year |
|---|---|
Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Humans; Prospective Studies; Proteomics; Pyrroles; Tumor Necrosis Factor Inhibitors; Venous Thromboembolism | 2022 |
5 other study(ies) available for pyrroles and Thromboembolism, Venous
| Article | Year |
|---|---|
Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme.
Topics: Adult; Aged; Cohort Studies; Colitis, Ulcerative; Female; Humans; Incidence; Male; Middle Aged; Piperidines; Pulmonary Embolism; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Venous Thromboembolism; Venous Thrombosis; Young Adult | 2019 |
Comparative Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Receiving Tofacitinib Versus Those Receiving Tumor Necrosis Factor Inhibitors: An Observational Cohort Study.
Topics: Adult; Aged; Arthritis, Rheumatoid; Cohort Studies; Databases, Factual; Female; Humans; Incidence; Janus Kinase Inhibitors; Male; Middle Aged; Piperidines; Proportional Hazards Models; Pulmonary Embolism; Pyrimidines; Pyrroles; Tumor Necrosis Factor Inhibitors; Venous Thromboembolism; Venous Thrombosis | 2019 |
Atorvastatin favorably modulates proinflammatory cytokine profile in patients following deep vein thrombosis.
Topics: Atorvastatin; C-Reactive Protein; Cytokines; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukins; P-Selectin; Pyrroles; Venous Thromboembolism | 2013 |
Altered fibrin clot properties in patients with retinal vein occlusion.
Topics: C-Reactive Protein; Coronary Artery Disease; Female; Fenofibrate; Fibrin; Fibrinolysis; Heptanoic Acids; Homocysteine; Humans; Hypersensitivity, Immediate; Laser Coagulation; Lipoprotein(a); Male; Pyrroles; Retinal Vein; Retinal Vein Occlusion; Simvastatin; Tetrahydroisoquinolines; Thrombosis; Venous Thromboembolism; Venous Thrombosis | 2011 |
Effects of atorvastatin on plasma fibrin clot properties in apparently healthy individuals and patients with previous venous thromboembolism.
Topics: Atorvastatin; Biomarkers; Blood Coagulation; Blood Coagulation Tests; Case-Control Studies; Dyslipidemias; Fibrin; Fibrinolytic Agents; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Poland; Pyrroles; Treatment Outcome; Ultrasonography, Doppler, Color; Venous Thromboembolism | 2012 |